Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

Syndax Pharmaceuticals (SNDX) EBIT Margin: 2015-2020

Historic EBIT Margin for Syndax Pharmaceuticals (SNDX) over the last 5 years, with Dec 2020 value amounting to -5,226.32%.

  • Syndax Pharmaceuticals' EBIT Margin fell 148816.00% to -5,226.32% in Q4 2020 from the same period last year, while for Dec 2020 it was -4,708.17%, marking a year-over-year decrease of 91523.00%. This contributed to the annual value of -1,434.43% for FY2024, which is 11198923.00% down from last year.
  • According to the latest figures from Q4 2020, Syndax Pharmaceuticals' EBIT Margin is -5,226.32%, which was up 0.23% from -5,238.26% recorded in Q3 2020.
  • In the past 5 years, Syndax Pharmaceuticals' EBIT Margin registered a high of -1,633.61% during Q4 2017, and its lowest value of -5,238.26% during Q3 2020.
  • Moreover, its 3-year median value for EBIT Margin was -4,544.99% (2018), whereas its average is -4,500.82%.
  • Per our database at Business Quant, Syndax Pharmaceuticals' EBIT Margin spiked by 201,917bps in 2017 and then tumbled by 345,402bps in 2018.
  • Over the past 5 years, Syndax Pharmaceuticals' EBIT Margin (Quarterly) stood at -3,652.79% in 2016, then soared by 201,917bps to -1,633.61% in 2017, then tumbled by 345,402bps to -5,087.63% in 2018, then skyrocketed by 134,947bps to -3,738.16% in 2019, then crashed by 148,816bps to -5,226.32% in 2020.
  • Its EBIT Margin stands at -5,226.32% for Q4 2020, versus -5,238.26% for Q3 2020 and -4,382.59% for Q2 2020.